Daily Digest

The Valve Wire

Monday, April 27, 2026

Executive Summary

Today's research roundup centers on aortic valve interventions, with three meta-analyses delivering important messages for TAVR practice: cerebral embolic protection devices (CEPDs) do not reduce stroke during TAVR — a finding the authors call conclusive based on trial sequential analysis of over 11,500 patients; patients with low-flow, low-gradient aortic stenosis face substantially worse long-term outcomes after TAVR compared to high-gradient disease; and the presence of coronary chronic total occlusions does not appear to increase short- or mid-term mortality after TAVI. On the industry side, Edwards Lifesciences surged nearly 6% while Boston Scientific fell over 5%, widening the divergence in the structural heart device space.

For the clinical audience: the CEPD meta-analysis is the most consequential publication today. Across 8 RCTs and nearly 12,000 patients, neither filter-based nor shield-based embolic protection devices reduced any stroke, disabling stroke, or mortality during TAVR — and trial sequential analysis suggests we have enough data to accept this null result. This has direct implications for device utilization, reimbursement, and ongoing trials. Meanwhile, the LFLG AS outcomes data reinforce that hemodynamic phenotyping matters profoundly for prognosis, even in the transcatheter era. Below, we unpack what these findings mean for practice, where the caveats lie, and what's moving in trials and markets.

Today's Key Findings

[NOTABLE] Cerebral embolic protection devices show NO benefit during TAVR — meta-analysis of 8 RCTs (n=11,597) with trial sequential analysis confirming sufficient evidence to reject predefined benefit thresholds (American Heart Journal)
Low-flow, low-gradient AS carries nearly double the 5-year mortality after TAVR compared to high-gradient disease (HR 1.92 for classical LFLG), with 4-fold higher HF hospitalization risk (JAHA)
Chronic total occlusions do not increase mortality after TAVI at in-hospital or 1-year follow-up, though MI risk is modestly higher (Future Cardiology)
Edwards Lifesciences (EW) jumped 5.6% while Boston Scientific (BSX) dropped 5.5%, reflecting sharp intraday divergence in the structural heart sector

Aortic Valve (TAVR/TAVI)

Cerebral Embolic Protection Devices: The Case Closes?

[NOTABLE] Elbenawi et al. performed a meta-analysis and trial sequential analysis (TSA) of 8 RCTs (5 filter-based, 3 shield-based) enrolling 11,597 TAVR patients comparing routine CEPD use versus no CEPD. The headline results: no significant reduction in any stroke (RR 0.92, 95% CI 0.75–1.14), disabling stroke (RR 0.80, 95% CI 0.55–1.15), new MRI-detected brain lesions (RR 1.00), or all-cause mortality (RR 1.04). Meta-regression found no subgroup that benefited — age, sex, diabetes, prior stroke, and atrial fibrillation were all non-significant moderators. Critically, TSA indicated the cumulative evidence crosses the futility boundary, suggesting additional trials of current-generation devices are unlikely to demonstrate benefit at prespecified thresholds.

Editorial perspective: This is a practice-relevant finding. Despite intuitive appeal and robust bench-testing showing debris capture, CEPDs have now failed to translate mechanical efficacy into clinical stroke reduction across a large, well-powered evidence base. Several caveats deserve attention: (1) periprocedural stroke after TAVR is multifactorial — thrombus formation, hemodynamic compromise, and delayed events are not addressable by embolic filters; (2) the analysis pools devices with different mechanisms (filter vs. shield), and individual device-level differences may exist; (3) the trials vary in endpoint adjudication rigor and imaging protocols. Nevertheless, the TSA component strengthens the conclusion substantially. For operators and institutions currently deploying CEPDs routinely, this evidence challenges that practice. For payers, this provides robust data to question routine reimbursement. The findings align with skepticism expressed by Kaul and others regarding device adoption outpacing evidence — CEPDs may represent a textbook case of "mechanistically logical but clinically unproven" technology.

Long-Term Outcomes in Low-Flow, Low-Gradient AS After TAVR

Soltani Moghadam et al. in JAHA present a reconstructed time-to-event meta-analysis of 19 observational studies (20,493 patients) comparing TAVR outcomes across hemodynamic AS phenotypes. At 5 years, classical LFLG AS carried an HR of 1.92 (95% CI 1.62–2.27) for all-cause mortality and paradoxical LFLG an HR of 1.20 (95% CI 1.07–1.34), both compared to high-gradient AS. Cardiovascular mortality was similarly elevated (classical LFLG HR 1.94; paradoxical LFLG HR 1.40). Perhaps most striking, classical LFLG AS was associated with a 4-fold increase in heart failure hospitalization (HR 4.12) compared to HG disease.

Editorial perspective: These findings, while derived from observational data with inherent confounding (LFLG patients are sicker at baseline with lower LVEF, more comorbidities), reinforce a crucial clinical reality: TAVR addresses the valve but does not cure the underlying myocardial disease driving low-flow physiology. The gradient distinction matters enormously for patient counseling and informed consent. The current guidelines — both ACC/AHA 2020 and ESC 2025 — recommend intervention for symptomatic low-flow low-gradient severe AS (Class I), but do not differentiate expected benefit by AS phenotype. This meta-analysis suggests they perhaps should, or at minimum that shared decision-making should explicitly incorporate the substantially worse prognosis for LFLG patients. The study is limited by its observational design, heterogeneous definitions of LFLG across included studies, and potential selection bias (some LFLG patients may have had misclassified moderate AS). Still, the magnitude and consistency of the signal are compelling.

Chronic Total Occlusions and TAVI Outcomes

Dimitriadis et al. in Future Cardiology analyzed 7 studies (15,162 TAVI patients) and found no significant difference in in-hospital mortality (RR 1.13) or 1-year all-cause mortality (RR 1.58, 95% CI 0.71–3.50) between patients with and without pre-procedural CTOs. Patients with CTOs had modestly higher MI rates (RR 1.27, 95% CI 1.07–1.51) and, interestingly, lower rates of new pacemaker implantation (RR 0.88). No differences were seen in cardiogenic shock, AKI, vascular complications, or bleeding.

Editorial perspective: This is reassuring for operators considering TAVI in patients with concomitant CTO — the presence of an unrevascularized CTO alone should not be a reason to defer valve intervention. However, the wide confidence intervals for 1-year mortality (0.71–3.50) suggest this question is far from settled, and individual CTO characteristics (territory at risk, collateral quality, LV function) likely matter more than the binary presence/absence of occlusion. The finding is consistent with the general principle from both guidelines that non-complex CAD does not mandate CABG as a prerequisite for valve intervention, though severe multivessel disease with CTO in a large territory remains a factor favoring SAVR + CABG per both ACC/AHA and ESC frameworks. Longer follow-up and patient-level data are needed, particularly for patients with CTOs supplying large myocardial territories.

Aortic Root Remodeling After TAVR

Liu et al. in BMC Cardiovascular Disorders published a pre-and-post-procedure CTA comparative analysis examining the impact of TAVR on aortic root geometry. No abstract was available at the time of this report. The topic is relevant to lifetime management planning — the ESC 2025 guidelines emphasize CT-based anatomical analysis at the index procedure to assess future valve-in-valve feasibility, coronary access risk, and sinus sequestration. We will cover the full findings when the abstract becomes available.

Surgical vs. Transcatheter Comparisons

No direct surgical vs. transcatheter comparison studies were published today, but the LFLG meta-analysis above has indirect relevance: outcomes for LFLG AS after TAVR are substantially worse than for high-gradient disease, yet no parallel meta-analysis of SAVR in LFLG AS was provided for direct comparison. Historical surgical data suggest similarly elevated mortality in LFLG patients after SAVR, particularly those with classical low-flow phenotype and reduced LVEF. The question of whether SAVR or TAVR provides superior outcomes in LFLG disease remains unanswered by randomized data — a notable gap given that both ACC/AHA 2020 and ESC 2025 guidelines recommend intervention (Class I) for this population without specifying modality preference based on flow status alone. The ongoing DEDICATE extended follow-up and future substudies may help clarify this.

Financial Analysis

Today's structural heart equity landscape showed sharp divergence. Edwards Lifesciences surged 5.56% to close at $84.15, its strongest single-day gain in months, while Boston Scientific plunged 5.51% to $62.07, touching new 52-week lows. Abbott also slipped 1.46% to $91.13, continuing its painful 6-month decline of 27.5%. The divergence is notable: Edwards, despite a mature TAVR franchise, appears to be attracting safe-haven flows within the medtech space, while BSX — which had been the sector's growth darling through 2025 — is facing a significant derating.

A notable institutional move surfaced today: Vanguard Group sold 283,775 shares of Edwards Lifesciences (MarketBeat), a modest trim for a passive index giant but worth flagging given the stock's recent momentum. Vanguard's position adjustments typically reflect index rebalancing rather than active views, so this should not be over-interpreted as bearish conviction.

The broader medtech sector faces macro headwinds from tariff uncertainty and healthcare budget pressures, but the structural heart subsector benefits from durable demographic tailwinds — aging populations, expanding transcatheter indications, and the ESC 2025 guideline expansions in tricuspid and asymptomatic AS that should drive volumes. Edwards' EVOQUE tricuspid replacement and PASCAL TEER platforms, plus Medtronic's Intrepid TMVR pipeline, represent the next growth vectors beyond the maturing TAVR market.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $84.15 | Daily Change: +$4.43 (+5.56%)
6-Month Performance: +4.12% | Volume: 11.8M (elevated)
Market Cap: $48.5B | P/E (trailing): 46.49 | P/E (forward): 25.04 | Beta: 0.94
52-Week Range: $72.30 – $87.89
Analyst Consensus: Buy | Target: $96.96 (range $84–$110, 27 analysts) — 15.2% upside
Next Earnings: July 23, 2026 | EPS est: $0.74 | Rev est: $1.70B

Edwards posted its strongest session in weeks, trading near the top of its 6-month range. The stock has quietly recovered from its October 2025 lows around $74.66, now sitting just 4% below its 52-week high. The forward P/E of 25x remains a premium to medtech peers but reflects the company's dominant TAVR franchise, expanding PASCAL TEER platform, and EVOQUE tricuspid replacement — all benefiting from the ESC 2025 guideline expansions. The Vanguard trim noted above is a rounding error for the stock but reflects the ongoing float adjustments in large-cap medtech. Watch the July earnings for updated TAVR volume trends and TMTT segment growth.

Medtronic (MDT)

Close: $83.32 | Daily Change: -$0.47 (-0.56%)
6-Month Performance: -10.11% | Volume: 6.6M
Market Cap: $107.0B | P/E (trailing): 23.27 | P/E (forward): 13.75 | Beta: 0.76
52-Week Range: $79.93 – $106.33
Analyst Consensus: Buy | Target: $108.00 (range $90–$121, 25 analysts) — 29.6% upside
Next Earnings: June 3, 2026 | EPS est: $1.55 | Rev est: $9.62B

Medtronic continues its slow bleed, down over 10% in six months and now 22% below its 52-week high. The diversified conglomerate model dilutes structural heart enthusiasm — the Evolut TAVR platform and Intrepid TMVR pipeline are bright spots, but they're buried in a $107B enterprise. The forward P/E of 13.75x is the cheapest in this peer group by far, reflecting market skepticism about growth acceleration. The June 3 earnings report will be closely watched for Evolut FX adoption trends and Intrepid pivotal trial enrollment updates. The gap between analyst targets ($108) and current price ($83) is the widest among these names — either analysts are too optimistic or the market is pricing in too much pessimism.

Abbott (ABT)

Close: $91.13 | Daily Change: -$1.35 (-1.46%)
6-Month Performance: -27.53% | Volume: 12.8M
Market Cap: $158.4B | P/E (trailing): 25.53 | P/E (forward): 15.03 | Beta: 0.78
52-Week Range: $90.72 – $139.06
Analyst Consensus: Buy | Target: $118.64 (range $92–$143, 25 analysts) — 30.2% upside
Next Earnings: July 16, 2026 | EPS est: $1.28 | Rev est: $12.54B

Abbott touched new 52-week lows today at $90.72 before closing marginally above. The 27.5% decline over six months is the most severe in this peer group and reflects broader headwinds beyond the structural heart portfolio — litigation exposure, diagnostic revenue normalization, and tariff concerns have all weighed on sentiment. The TriClip franchise (TRILUMINATE Pivotal, now active not recruiting) and MitraClip Gen 5 pipeline are strong structural heart assets, but they represent a small fraction of Abbott's $42B+ annual revenue. For structural heart specifically, the MitraClip G5 registry (NCT07543874) launching soon and REPAIR-MR pivotal trial readout will be key catalysts. At 15x forward earnings, Abbott offers value if macro headwinds ease.

Boston Scientific (BSX)

Close: $62.07 | Daily Change: -$3.62 (-5.51%)
6-Month Performance: -39.40% | Volume: 17.7M (very elevated)
Market Cap: $92.2B | P/E (trailing): 25.97 | P/E (forward): 16.44 | Beta: 0.78
52-Week Range: $59.39 – $109.50
Analyst Consensus: Strong Buy | Target: $85.94 (range $69–$110, 31 analysts) — 38.5% upside
Next Earnings: July 22, 2026 | EPS est: $0.83 | Rev est: $5.40B

BSX had its worst session in recent memory, plunging 5.5% on massive volume and closing near its 52-week low. The stock has lost nearly 40% in six months — a stunning reversal for what was a consensus growth name through mid-2025. While BSX's structural heart exposure is more limited than Edwards' (focused on interventional cardiology and the ACURATE neo2 TAVR platform in select markets), the broader sell-off reflects concerns about procedure volume growth and competitive positioning. The 31-analyst consensus of "Strong Buy" with a $86 target implies significant dislocation between analyst models and market pricing. BSX's WATCHMAN franchise for left atrial appendage occlusion complements structural heart capabilities, but the market is demanding proof of durable growth acceleration.

Anteris Technologies (AVR.AX)

Close: A$7.60 | Daily Change: Flat (weekend)
6-Month Performance: -13.64% | Volume: N/A
Market Cap: A$0.7B | P/E (forward): -3.49 (pre-revenue) | Beta: 0.55
52-Week Range: A$4.68 – A$9.79
Analyst Target: A$13.00 (1 analyst)

Anteris remains a clinical-stage story with its DurAVR transcatheter heart valve — a single-piece, 3D-printed TAVR prosthesis using ADAPT anti-calcification tissue. The DurAVR pivotal trial (NCT07194265) is actively recruiting with a target of 1,650 patients, comparing against SAPIEN and Evolut platforms. At A$0.7B market cap, the stock is a pure play on next-generation TAVR differentiation. The 6-month decline of 14% reflects the typical volatility of clinical-stage medtech, though the stock has roughly doubled from its 52-week low of A$4.68. Catalyst: pivotal trial enrollment milestones and interim safety data.

Note: JenaValve Technology, J Valve Technology, and Meril Life Sciences are private companies with no publicly available stock data.

Market outlook: The structural heart sector is experiencing a notable bifurcation. Edwards, the purest-play structural heart name, is outperforming while diversified device companies (Abbott, BSX, Medtronic) face broader macro headwinds. This suggests the market remains constructive on structural heart procedure volumes — buoyed by ESC 2025 guideline expansions in tricuspid, asymptomatic AS, and secondary MR — even as it reprices growth expectations for the broader medtech universe. The upcoming Q2/Q3 earnings cycle (June–July) will test whether procedure volume growth can sustain premium valuations against a tougher macro backdrop.

Clinical Trial Updates

Aortic Valve Trials

ULTRA-EVOLUT RCT (NCT07545369) — A Comparison of Latest-Generation TAVR Valves: SAPIEN 3 Ultra Resilia vs. Evolut FX | Status: Not Yet Recruiting | Enrollment: 200 | Sponsor: Assiut University | A head-to-head RCT of current-generation balloon- vs. self-expandable valves — an important comparative effectiveness question given the absence of contemporary randomized comparisons between these platforms.
Alternative Peripheral TAVI Accesses (NCT07539909) — Status: Not Yet Recruiting | Enrollment: 600 | Sponsor: Medical University of Silesia | Registry evaluating non-transfemoral TAVI access routes — relevant as guidelines emphasize transfemoral-first approach but alternatives remain important for anatomically unsuitable patients.
ECHO-TAVR (NCT07317804) — Echo-Guided vs Fluoroscopy-Guided TAVR | Phase 4 | Status: Not Yet Recruiting | Enrollment: 212 | Sponsor: China National Center for Cardiovascular Diseases | Explores echo-guided TAVR to reduce radiation and contrast exposure.
TAVI in Cardiogenic Shock (TACTICS) (NCT06638268) — Status: Recruiting | Enrollment: 30 | Sponsor: Rigshospitalet | Comparing acute vs. stabilization-then-subacute TAVI in AS-related cardiogenic shock — a high-risk population with limited evidence.
EMPagliflozin After Aortic Valve Replacement (NCT06171802) — Phase 4 | Status: Active, Not Recruiting | Enrollment: 205 | Sponsor: Rigshospitalet | Investigating SGLT2i benefit post-AVR — could establish a new pharmacological adjunct to valve intervention.
Conestat Alfa for Cerebral/Renal Protection Post-TAVI (NCT05145283) — Phase 2 | Status: Completed | Enrollment: 141 | Sponsor: University Hospital Basel | Results pending for this pharmacological neuroprotection approach — notable given today's CEPD futility data.
Comparison of Eligible TAVI Valves – Cohort B (NCT04443023) — Status: Completed | Enrollment: 1,031 | Sponsor: Aarhus University Hospital | Large comparative TAVI valve cohort — results anticipated.
DurAVR Pivotal Trial (NCT07194265) — Status: Recruiting | Enrollment: 1,650 | Sponsor: Anteris Technologies | Pivotal trial for the next-generation single-piece TAVR prosthesis vs. SAPIEN/Evolut.
Preoperative Dental Screening Before Valve Surgery/TAVI (NCT07511673) — Status: Not Yet Recruiting | Enrollment: 1,300 | Sponsor: Region Skane | Novel RCT testing whether dental screening reduces endocarditis and other complications post-valve intervention.
EasyCross Self-Centering Catheter (NCT06412354) — Status: Completed | Enrollment: 20 | Sponsor: Vivheart | First-in-human study of a catheter navigation device.
RAFT-TAVR PACE (NCT06857201) — Status: Withdrawn | This trial comparing left bundle branch area pacing vs. RV pacing post-TAVR in patients requiring permanent pacemaker has been withdrawn before enrollment. A missed opportunity — conduction disturbance management post-TAVR remains an important unresolved question.

Aortic Valve Landmark Trials

[LANDMARK] Evolut Low Risk Long-Term Follow-Up (NCT02701283) — Status: Active, Not Recruiting | Enrollment: 2,223 | Sponsor: Medtronic | Long-term follow-up of the pivotal low-risk TAVR trial. Extended data beyond 5 years are critical for the durability debate and directly inform the ESC 2025 decision to recommend TAVI for patients ≥70 with tricuspid AV. Every additional year of follow-up matters enormously.

Mitral Repair Trials

GeminiOne TEER System FIH (NCT07086534) — Status: Recruiting | Enrollment: 15 | Sponsor: Sierra Valve LLC | First-in-human study of a new TEER device — the competitive landscape for MitraClip and PASCAL continues to expand.
MitraClip Gen 5 Registry (NCT07543874) — Status: Not Yet Recruiting | Enrollment: 1,000 | Sponsor: University Hospital of Cologne | Large registry for the latest-generation MitraClip — will provide real-world data on iterative device improvements.
MITRA-REVERSE (NCT02924363) — Status: Completed | Enrollment: 54 | Sponsor: Dipan Shah | CMR-based assessment of reverse remodeling after MitraClip — results anticipated.

Mitral Repair Landmark Trials

[LANDMARK] REPAIR-MR (NCT04198870) — MitraClip vs. Surgery for Primary MR | Status: Active, Not Recruiting | Enrollment: 500 | Sponsor: Abbott | This is the most anticipated head-to-head comparison of TEER vs. surgical repair for primary MR. Both ACC/AHA 2020 and ESC 2025 maintain surgery as the gold standard for primary MR — REPAIR-MR could reshape that hierarchy. Results will directly inform whether TEER should be offered to lower-risk primary MR patients. Currently, TEER for primary MR holds only a Class IIa recommendation for high-surgical-risk patients.
[LANDMARK] PRIMATY (NCT05051033) — MitraClip vs. Medical Therapy for Secondary MR | Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns | US-based confirmatory trial for TEER in secondary MR, enrolling broader criteria than COAPT. Will test whether the ESC 2025 Class I upgrade for TEER in ventricular SMR is generalizable beyond COAPT-like patients.
[LANDMARK] COAPT Long-Term Follow-Up (NCT03706833) — Status: Active, Not Recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences | Now includes both PASCAL and MitraClip arms. The COAPT 5-year data drove the ESC 2025 upgrade of TEER for ventricular SMR to Class I, LOE A. Longer follow-up will test durability of benefit.

Mitral Replacement Landmark Trials

[LANDMARK] Intrepid TMVR Pivotal (NCT03242642) — Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic | The largest TMVR pivotal trial, evaluating the Intrepid valve for severe MR in surgical-risk patients. TMVR remains earlier in development than TEER — success here could offer a complete replacement solution for patients unsuitable for repair.

Tricuspid Repair Landmark Trials

[LANDMARK] TRILUMINATE Pivotal (NCT03904147) — Status: Active, Not Recruiting | Enrollment: 572 | Sponsor: Abbott | The foundational trial for TriClip TEER in tricuspid regurgitation. Positive results drove the ESC 2025 Class IIa recommendation for transcatheter TR treatment — the first guideline-level endorsement of transcatheter tricuspid therapy.
[LANDMARK] CLASP II TR (NCT04097145) — Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences | PASCAL TEER system for TR. Edwards' entry into the tricuspid TEER space, competing directly with Abbott's TriClip.

Tricuspid Replacement Landmark Trials

[LANDMARK] TRISCEND II (NCT04482062) — Status: Active, Not Recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences | Evoque transcatheter tricuspid valve replacement vs. medical therapy. Showed superior symptom relief but higher bleeding and pacemaker rates than TEER approaches — the repair-vs-replace debate for the tricuspid valve is just beginning.

Other Relevant Trials

Triple Combination Therapy in Advanced HFpEF (NCT06655480) — Phase 2 | Status: Recruiting | Enrollment: 50 | Sponsor: National Medical Research Center for Cardiology, Russia | Testing ARNI + SGLT2i + MRA in HFpEF — relevant to structural heart as many HFpEF patients have concurrent valvular disease (atrial functional MR, TR).
MRI-Guided Heart Catheterization (NCT03152773) — Status: Suspended | Enrollment: 22 | Sponsor: NHLBI | MRI fluoroscopy with passive guidewires — suspension likely reflects technical/regulatory hurdles in this early-stage imaging approach.
NHLBI-Emory Advanced Cardiac CT Reconstruction (NCT05372627) — Status: Not Yet Recruiting | Enrollment: 1,000 | Sponsor: NHLBI | Advanced CT reconstruction techniques relevant to TAVR planning and post-procedural surveillance imaging.

Closing Thought

Today's CEPD meta-analysis is a sobering reminder that biological plausibility does not guarantee clinical efficacy — a lesson the structural heart field would do well to internalize as it expands into new valve territories and younger populations. The evidence bar for routine device adoption should be high. Tomorrow, we'll be watching for updates from the CLASP II TR enrollment and any emerging data from the completed Conestat alfa neuroprotection trial. Until then, read critically and demand the data.

— E. Nolan Beckett, The Valve Wire

← April 24, 2026